002873.SZ
Guiyang Xintian Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 8.39
−0.59%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 735.2M | 749.7M | 857.5M | 954.0M | 1.1B |
| Cost of Revenue | 207.1M | 213.1M | 227.7M | 218.8M | 247.3M |
| Gross Profit | 528.1M | 536.6M | 629.9M | 735.2M | 840.4M |
| Operating Expenses | |||||
| R&D Expense | 42.7M | 42.6M | 40.5M | 38.1M | 21.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 125.3M | 127.9M | 142.0M | 151.5M | 141.8M |
| Selling & Marketing Expense | 321.3M | 328.8M | 371.6M | 437.5M | 532.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 521.2M | 531.1M | 587.1M | 652.2M | 719.9M |
| Cost and Expenses | 728.3M | 744.2M | 814.8M | 871.0M | 967.2M |
| Operating Income (EBIT) | 10.5M | 10.1M | 63.2M | 93.7M | 121.9M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 10.5M | 9.8M | 60.8M | 92.4M | 121.3M |
| Income Tax Expense | 2.1M | 658.0K | 8.4M | 11.5M | 9.8M |
| Bottom Line | |||||
| Net Income | 8.4M | 9.1M | 52.3M | 80.9M | 111.5M |
| Earnings from Cont. Ops | 8.4M | 9.1M | 52.3M | 80.9M | 111.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 8.4M | 9.1M | 52.3M | 80.9M | 111.5M |
| Per Share | |||||
| Basic EPS | CN¥0.03 | CN¥0.04 | CN¥0.24 | CN¥0.35 | CN¥0.48 |
| Diluted EPS | CN¥0.03 | CN¥0.04 | CN¥0.24 | CN¥0.33 | CN¥0.46 |
| Revenue Per Share | CN¥3.01 | CN¥3.18 | CN¥3.89 | CN¥4.12 | CN¥4.69 |
| Shares | |||||
| Basic Shares Outstanding | 244.4M | 235.4M | 220.3M | 231.8M | 231.9M |
| Diluted Shares Outstanding | 244.4M | 235.4M | 220.3M | 231.8M | 231.9M |
| Profitability Metrics | |||||
| EBITDA | — | 49.8M | 97.1M | 115.6M | 147.8M |
| D&A | — | 39.7M | 33.9M | 21.8M | 25.9M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026